目的 探究α-酮酸聯(lián)合碳酸鈣改善維持性血液透析患者鈣磷代謝的臨床療效。方法 選取2015年1月-2015年7月在崇州市人民醫(yī)院進行維持性血液透析治療的患者82例，隨機分為對照組與治療組，每組各41例。對照組患者口服碳酸鈣D3片，600 mg/次，2次/d。治療組在對照組基礎上，餐中口服復方α-酮酸片，4片/次，3次/d。兩組的治療時間不低于6個月。分析兩組患者治療前、治療后3、6個月血液中鈣磷的量、鈣磷乘積、血清中堿性磷酸酶（AKP）、甲狀旁腺激素（PTH）水平、血白蛋白含量、綜合性營養(yǎng)評估（SGA）及BMI指數(shù)的變化情況。結果 治療后3、6個月，兩組患者的血磷量和鈣磷乘積明顯降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組的降低程度優(yōu)于對照組（P<0.05）。治療后3、6個月，兩組PTH值均降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組的PTH值顯著低于同期對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后3、6個月，兩組血白蛋白量、SGA評分、BMI指數(shù)均得到改善，同組治療前后差異具有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標顯著優(yōu)于同期對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 復方α-酮酸聯(lián)合碳酸鈣能明顯改善維持性血液透析患者的鈣磷代謝情況，提高患者的營養(yǎng)狀況，可有效的預防并發(fā)癥發(fā)生。

Objective To observe the clinical effects of α-ketoacid combined with calcium carbonate in improvement of calcium and phosphorus metabolism in patients with maintenance hemodialysis. Methods Patients (82 cases) with maintenance hemodialysis in Chongzhou Hospital from January in 2015 to July in 2015 were randomly divided into control group and treatment group, and each group had 41 cases. The patients in the control group were po administered with Calcium Carbonate D3 Tablets, 600 mg/time, twice daily. The patients in the treatment group were po administered with Compound α-Ketoacid Tablets during the meals on the basis of the control group, 4 tablets/time, three times daily. The treatment time of two groups was not less than 6 months. Calcium and phosphorus, calcium-phosphorus product, AKP, PTH, serum albumin, SGA scores, and BMI in two groups before treatment and after treatment for 3 and 6 months were compared. Results After treatment for 3 and 6 months, blood phosphorus and calcium-phosphorus product in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decreased degree in the treatment group was better than that in the control group (P<0.05). After treatment for 3 and 6 months, PTH values in two groups were significantly decreased, and there were differences in the same group (P<0.05). And PTH values in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 3 and 6 months, serum albumin, SGA scores, and BMI in two groups were improved, and the difference was statistically significant in the same group (P<0.05). And these observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Compound α-ketoacid combined with calcium carbonate can improve calcium and phosphorus metabolism in patients with maintenance hemodialysis and their nutritional status, which also can prevent complications effectively.